Covetrus, Inc. (NASDAQ:CVET) Receives Consensus Rating of "Buy" from Analysts

Thursday, April 8, 2021 | MarketBeat

Shares of Covetrus, Inc. (NASDAQ:CVET) have been given an average rating of "Buy" by the six ratings firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $33.25.

Several equities analysts recently issued reports on CVET shares. Barclays assumed coverage on Covetrus in a research report on Wednesday, February 17th. They issued an "overweight" rating and a $48.00 price target on the stock. Zacks Investment Research cut Covetrus from a "buy" rating to a "hold" rating in a research note on Tuesday. Finally, Raymond James lifted their price objective on shares of Covetrus from $31.00 to $39.00 and gave the company an "outperform" rating in a research report on Monday, March 8th.

In other Covetrus news, CEO Benjamin Wolin sold 5,556 shares of the company's stock in a transaction dated Wednesday, February 10th. The shares were sold at an average price of $38.34, for a total transaction of $213,017.04. Also, insider Anthony C. Jr. Providenti sold 5,000 shares of the stock in a transaction dated Friday, January 15th. The shares were sold at an average price of $36.78, for a total transaction of $183,900.00. Following the completion of the transaction, the insider now directly owns 20,540 shares of the company's stock, valued at $755,461.20. The disclosure for this sale can be found here. Insiders have sold a total of 57,442 shares of company stock worth $1,993,806 in the last quarter. 1.20% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new stake in Covetrus in the third quarter valued at $29,000. Eudaimonia Partners LLC acquired a new stake in Covetrus during the third quarter worth approximately $43,000. Assetmark Inc. grew its stake in Covetrus by 25.2% in the 4th quarter. Assetmark Inc. now owns 2,075 shares of the company's stock worth $60,000 after acquiring an additional 417 shares during the period. Annapolis Financial Services LLC acquired a new position in Covetrus in the 4th quarter valued at $77,000. Finally, Scott Investment Partners LLP purchased a new position in shares of Covetrus during the 4th quarter worth $83,000. 94.10% of the stock is owned by hedge funds and other institutional investors.

Shares of Covetrus stock opened at $29.15 on Thursday. The company has a quick ratio of 1.34, a current ratio of 2.05 and a debt-to-equity ratio of 0.76. Covetrus has a 52 week low of $6.87 and a 52 week high of $40.78. The firm's 50 day moving average is $32.66 and its two-hundred day moving average is $30.10. The firm has a market capitalization of $3.97 billion, a P/E ratio of -52.05, a P/E/G ratio of 2.64 and a beta of 2.28.

Covetrus (NASDAQ:CVET) last issued its quarterly earnings data on Sunday, February 28th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.16 by $0.05. Covetrus had a negative net margin of 1.21% and a positive return on equity of 7.09%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the firm posted $0.18 EPS. Covetrus's revenue for the quarter was up 11.2% on a year-over-year basis. As a group, research analysts expect that Covetrus will post 0.6 earnings per share for the current fiscal year.

About Covetrus

Covetrus, Inc, together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, and vitamins and supplements to wholesale and retail customers.

Further Reading: What is the Russell 2000 Index?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What is the Quick Ratio?



7 Stocks It May Be Time To Take Profits On

Should you or shouldn’t you? Many investors are wondering if it’s time to take some profit. With so much uncertainty in the market, there can be a temptation to take your profits and run. That may or may not be a good strategy. It’s true there are some speculative stocks that are going up on nothing but faith, trust, and pixie dust. But there are other stocks that may still be good buys despite continuing to grow.

Since the sell-off caused by the novel coronavirus and subsequent locking down of large portions of the economy, the stock market has recovered nearly all of its losses. The Federal Reserve has done its part by pledging to keep interest rates low for as long as it takes. New housing starts are up. Unemployment is coming down. There seems to be a lot of fuel for market bulls.

Still, if you’ve been holding one of the stocks in this presentation, it may be time for you to take some of the profits you’ve made. Many of the stocks in this presentation are being downgraded by analysts. And that means that there is likely to be downward pressure on the stock price.

View the "7 Stocks It May Be Time To Take Profits On".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.